Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2028 revenue reaching $2M — -48.1% growth in a single year.
What Moves the Stock
01Phase IIb/III clinical trial data readouts for eftilagimod alpha in metastatic breast cancer (TACTI-003 trial) and head/neck cancer - positive efficacy data can drive 50-100%+ moves
02Partnership expansion announcements or milestone payment triggers from existing deals with Merck KGaA, Merck & Co., or new pharma collaborations
03Regulatory milestone achievements: IND filings, Fast Track designations, Breakthrough Therapy designations, or BLA/NDA submissions
04Cash position updates and equity financing announcements - dilutive raises typically pressure stock 10-30%, while non-dilutive partnerships provide support
05Competitive LAG-3 data from Bristol-Myers Squibb (relatlimab) or other immuno-oncology competitors affecting platform validation
06Partnership milestone payments and upfront licensing fees (currently primary revenue source, ~100% of minimal revenue)
07Future royalties on partnered products if commercialized (not yet generating material revenue)
08Potential product sales post-approval (no approved products as of February 2026)
Rising interest rates create significant valuation pressure on pre-revenue biotechs through two mechanisms: (1) higher discount rates…
Watch on earnings: TACTI-003 trial interim analysis results and overall survival data readout timing (primary value catalyst), Quarterly cash burn rate and total cash/equivalents balance (runway visibility), Clinical trial patient enrollment progress versus guidance across all active studies.
One Sentence Summary:
Immutep: the story is balanced — phase iib/iii clinical trial data readouts for eftilagimod alpha in metastatic breast cancer (tacti-003 trial) and head/neck cancer.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
